Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis : a prospective, observational real-life study
BACKGROUND: Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management.
OBJECTIVES: The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment.
METHODS: We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy.
RESULTS: The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value <0.05) compared to Group A.
CONCLUSIONS: Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:171 |
|---|---|
| Enthalten in: |
La Clinica terapeutica - 171(2020), 4 vom: 21. Juli, Seite e310-e315 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bernardini, N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 08.09.2020 Date Revised 08.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7417/CT.2020.2234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311921884 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311921884 | ||
| 003 | DE-627 | ||
| 005 | 20231225143308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7417/CT.2020.2234 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311921884 | ||
| 035 | |a (NLM)32614364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bernardini, N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis |b a prospective, observational real-life study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2020 | ||
| 500 | |a Date Revised 08.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management | ||
| 520 | |a OBJECTIVES: The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment | ||
| 520 | |a METHODS: We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy | ||
| 520 | |a RESULTS: The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value <0.05) compared to Group A | ||
| 520 | |a CONCLUSIONS: Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Psoriasis treatment | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Ointments |2 NLM | |
| 700 | 1 | |a Skroza, N |e verfasserin |4 aut | |
| 700 | 1 | |a Tolino, E |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesiello, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mambrin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Balduzzi, V |e verfasserin |4 aut | |
| 700 | 1 | |a Michelini, S |e verfasserin |4 aut | |
| 700 | 1 | |a Maddalena, P |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, S |e verfasserin |4 aut | |
| 700 | 1 | |a Proietti, I |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Clinica terapeutica |d 1958 |g 171(2020), 4 vom: 21. Juli, Seite e310-e315 |w (DE-627)NLM000039187 |x 1972-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:171 |g year:2020 |g number:4 |g day:21 |g month:07 |g pages:e310-e315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7417/CT.2020.2234 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 171 |j 2020 |e 4 |b 21 |c 07 |h e310-e315 | ||